<?xml version="1.0" encoding="UTF-8"?>
<p id="Par17">We applied a published model that includes viral suppression by both the immune response and antiviral treatment
 <sup>
  <xref ref-type="bibr" rid="CR10">10</xref>,
  <xref ref-type="bibr" rid="CR11">11</xref>
 </sup>, as given by dU/dt = −bUV;  dF/dt = bUV−δF; dZ/dt = rZ; dV/dt = (1−ϵ)pF-cV-kZV. The variables 
 <italic>U, F</italic>, 
 <italic>Z</italic>, and 
 <italic>V</italic> represent the numbers of uninfected target cells, the numbers of infected target cells, the intensity of the immune response (i.e., antibody levels), and the amount of free virus (in TCID
 <sub>50</sub>/ml), respectively. The parameters 
 <italic>p</italic>, 
 <italic>c, b</italic>, 
 <italic>r</italic>, and 
 <inline-formula id="IEq3">
  <alternatives>
   <tex-math id="M5">\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\epsilon$$\end{document}</tex-math>
   <math id="M6">
    <mi>ϵ</mi>
   </math>
   <inline-graphic xlink:href="41467_2020_16585_Article_IEq3.gif" xmlns:xlink="http://www.w3.org/1999/xlink"/>
  </alternatives>
 </inline-formula> denote the viral replication rate, viral death rate, cell infection rate, growth rate of the immune response, and the antiviral efficacy. Using published estimates for the initial values of 
 <italic>F</italic> and 
 <italic>U</italic>
 <sup>
  <xref ref-type="bibr" rid="CR10">10</xref>
 </sup>, we applied simulated annealing and approximate Bayesian computation
 <sup>
  <xref ref-type="bibr" rid="CR38">38</xref>,
  <xref ref-type="bibr" rid="CR39">39</xref>
 </sup> to fit the model to clinical trial data
 <sup>
  <xref ref-type="bibr" rid="CR8">8</xref>
 </sup> to estimate all model parameters. We assumed that the time from infection to symptom onset follows a lognormal distribution, 
 <italic>L</italic>, and the time from symptom onset to treatment follows a gamma distribution truncated at 48 h, 
 <italic>G</italic>
 <sub>0–48</sub> (ref. 
 <sup>
  <xref ref-type="bibr" rid="CR40">40</xref>
 </sup>) the two distributions were estimated from data provided in refs. 
 <sup>
  <xref ref-type="bibr" rid="CR8">8</xref>,
  <xref ref-type="bibr" rid="CR41">41</xref>
 </sup> using the interior-point method to minimize the root-mean-square error (Supplementary Fig. 
 <xref rid="MOESM1" ref-type="media">2</xref>). We do not explicitly consider other sources of heterogeneity in viral replication or immune response rates. Although most of the patients in the trial were infected by influenza A viruses, ~10% were infected by influenza B viruses. When we consider the reduced efficacy of baloxavir against influenza B viruses relative to influenza A viruses
 <sup>
  <xref ref-type="bibr" rid="CR42">42</xref>
 </sup>, the predictions are relatively unchanged (Supplementary Fig. 
 <xref rid="MOESM1" ref-type="media">7</xref>). Following refs. 
 <sup>
  <xref ref-type="bibr" rid="CR14">14</xref>,
  <xref ref-type="bibr" rid="CR15">15</xref>
 </sup>, we assume that infectiousness is a logarithmic function of viral load, as given by 
 <inline-formula id="IEq4">
  <alternatives>
   <tex-math id="M7">\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$1 - e^{ - {\mathrm{log}}_{10}{\mathrm{V}}(t)/100}$$\end{document}</tex-math>
   <math id="M8">
    <mn>1</mn>
    <mo>−</mo>
    <msup>
     <mrow>
      <mi>e</mi>
     </mrow>
     <mrow>
      <mo>−</mo>
      <msub>
       <mrow>
        <mi mathvariant="normal">log</mi>
       </mrow>
       <mrow>
        <mn>10</mn>
       </mrow>
      </msub>
      <mi mathvariant="normal">V</mi>
      <mrow>
       <mo>(</mo>
       <mrow>
        <mi>t</mi>
       </mrow>
       <mo>)</mo>
      </mrow>
      <mo>/</mo>
      <mn>100</mn>
     </mrow>
    </msup>
   </math>
   <inline-graphic xlink:href="41467_2020_16585_Article_IEq4.gif" xmlns:xlink="http://www.w3.org/1999/xlink"/>
  </alternatives>
 </inline-formula> where 
 <italic>V(t)</italic> denotes the virus load at time 
 <italic>t</italic> since infection (Supplementary Section 
 <xref rid="MOESM1" ref-type="media">2</xref>). To estimate total reduction in infectiousness attributable to treatment, we calculate the area between the infectiousness curves estimated for placebo and treatment throughout the entire period of viremia.
</p>
